# **Special Issue**

# Renal Cell Carcinoma: From Diagnosis to Identification of Novel Therapeutic Targets and Minimally Invasive Treatments

# Message from the Guest Editors

Renal cell carcinoma (RCC) is the most frequent malignancy affecting the adult kidney and the twelfth most common cancer. The pathophysiology of RCC is complex and arises from a combination of gene mutations (i.e., VHL, PBMR1, SETD2, BAP1, etc.) in addition to other factors such as diabetes, obesity, smoking, and hypertension. In the early stages, the disease is frequently asymptomatic and incidentally diagnosed by imaging, having a good prognosis; conversely, RCC has a high mortality rate in advanced phases, due to poor responses to radiotherapy and chemotherapy. The progressive introduction of highthroughput technologies and recent studies of molecular and genomic profiling have shed new light on the pathophysiology of RCC. Moreover, in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters. This Special Issue of *Diagnostics* aims to collect studies on minimally invasive treatment and translational research for the management and diagnosis of renal cell carcinoma (RCC). This is the joint Special Issue both in *Biomedicines* and *Diagnostics*.

### **Guest Editors**

Dr. Matteo Ferro

Prof. Dr. Andrea Minervini

Prof. Dr. Alessandro Antonelli

Dr. Angelo Porreca

Prof. Dr. Giuseppe Lucarelli

Prof. Dr. Michele Battaglia

et al.

#### Deadline for manuscript submissions

closed (31 August 2022)



# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/85806

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

## Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

